CTX120 for Multiple Myeloma

Recruiting at 9 trial locations

Overseen By Clinical Trials

Age: 18+

Sex: Any

Trial Phase: Phase 1

Sponsor: CRISPR Therapeutics AG

Must not be taking: Steroids, Immunosuppressants, Antitumor, others

Disqualifiers: CNS pathology, HIV, Hepatitis, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: 1

Duration: 1 day

26 Participants Needed

Trial Summary

What is the purpose of this trial?

This trial is testing a new treatment called CTX120. It is aimed at patients with a type of blood cancer that has come back or not responded to other treatments. The goal is to see if CTX120 is safe and effective in these patients.

Research Team

Annie Weaver, PhD

Principal Investigator

CRISPR Therapeutics

Eligibility Criteria

This trial is for adults over 18 with multiple myeloma that has come back or hasn't responded to treatment after at least two prior therapies. They must be fairly active and healthy, with good organ function, and willing to use birth control for a year post-treatment. People can't join if they've had certain other treatments like gene therapy, have heart issues or infections like HIV, are pregnant/breastfeeding, or have serious mental health conditions.

Inclusion Criteria

I am 18 years old or older.

I am fully active or can carry out light work.

My multiple myeloma has returned or didn't respond to treatment, and I've had at least 2 prior treatments.

Exclusion Criteria

I do not have active HIV, hepatitis B, or hepatitis C.

I have had cancer before, but it was either skin cancer treated by surgery, cervical cancer that did not spread, or any cancer that was removed and has been in remission for over 5 years.

I am not pregnant or breastfeeding.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Lymphodepleting Chemotherapy

Participants receive lymphodepleting chemotherapy prior to CTX120 infusion

1-2 weeks

Treatment

CTX120 is administered by IV infusion

1 day

1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

28 days

Long-term Follow-up

Participants are monitored for objective response rate up to 60 months post-infusion

60 months

Treatment Details

Interventions

• CTX120

Trial Overview The study is testing CTX120's safety and effectiveness in treating relapsed or refractory multiple myeloma. It's an early-phase (Phase 1), single-arm trial where all participants receive the same experimental therapy without a comparison group.

Participant Groups

Group I: CTX120 Experimental Treatment 1 Intervention

Administered by IV infusion following lymphodepleting chemotherapy.

Who Is Running the Clinical Trial?

CRISPR Therapeutics AG

Lead Sponsor

Trials

9

Recruited

640+